Strategies used to access CFTR modulators in countries without reimbursement agreements
Journal of Cystic Fibrosis · 2025
DOI: 10.1016/j.jcf.2025.02.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2025. Verfasst von Jonathan Guo und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Faculty of Medicine, Imperial College London, United Kingdom. Electronic address: jyg17@ic.ac.uk. Hauptthemen laut MEDLINE: Cystic Fibrosis, Health Services Accessibility, Cystic Fibrosis Transmembrane Conductance Regulator, Reimbursement Mechanisms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, NIHR Imperial Biomedical Research Centre.
Abstract (Originalsprache)
CFTR modulators represent the international standard of care for the treatment of cystic fibrosis (CF). Yet due to prices of over $250,000 per year they are functionally inaccessible for people with CF (pwCF) unless reimbursed by healthcare systems. Current prices are unaffordable for payors in almost all low- and middle-income countries (LMICs) worldwide, and resulting disparities in access are widening existing global health inequities. In comparable situations in other therapeutic areas, patients have successfully developed strategies to bypass national reimbursement systems and gain access to treatment. We therefore undertook an international survey of CF clinicians in 15 countries where CFTR modulators are not reimbursed, to characterise alternative means of accessing modulator therapy. Successful methods were identified in 11 countries, and could broadly be categorised into legal challenges to access originator modulators, use of generic formulations, and access via donations. Aside from domestically produced generics used in Argentina and an originator-led donation program in Ukraine, these methods were only able to provide treatment to limited proportions of the local CF population due to significant associated financial costs. Accordingly, they are generally not sustainable or widely applicable, and fail to address the underlying structural issues driving international disparities in access. Twelve years after the initial marketing of CFTR modulators, pwCF in LMICs are being forced to take extraordinary measures to access disease-modifying treatment. Corrective measures are urgently required to overcome barriers posed by restrictive patents and prohibitively high prices, and to promote global health equity for pwCF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Public Health, Faculty of Medicine, Imperial College London, United Kingdom. Electronic address: jyg17@ic.ac.uk.
- School of Public Health, Faculty of Medicine, Imperial College London, United Kingdom.
- Department of Pharmacology and Therapeutics, University of Liverpool, United Kingdom.
Förderung
- National Institute for Health and Care Research
- NIHR Imperial Biomedical Research Centre
Zitieren
APA
Guo, J., Hennessy, G., Young, B., & Hill, A. (2025). Strategies used to access CFTR modulators in countries without reimbursement agreements. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2025.02.010
Vancouver
Guo J, Hennessy G, Young B, Hill A. Strategies used to access CFTR modulators in countries without reimbursement agreements. Journal of Cystic Fibrosis. 2025. doi:10.1016/j.jcf.2025.02.010
BibTeX
@article{Guo2025,
author = {Guo, Jonathan and Hennessy, Grace and Young, Benedict and Hill, Andrew},
title = {Strategies used to access CFTR modulators in countries without reimbursement agreements},
journal = {Journal of Cystic Fibrosis},
year = {2025},
doi = {10.1016/j.jcf.2025.02.010}
}
EUVIMED